Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on LinkedIn:
“With ASCO 2026 just around the corner, it is my great pleasure to contribute by presenting in the oral abstract session for early-stage NSCLC/SCLC, alongside prominent colleagues and chairs, the intracranial efficacy data of tarlatamab from DeLLphi-304 trial, the first data on CNS efficacy of a T-cell engager in SCLC.
Stay tuned!
Sunday June 1st, 13:15-16:15, Hall D1, Mc Cormick Convention Center, Chicago.”
Other articles featuring Giannis Mountzios on OncoDaily.